Analysts’ Recent Ratings Updates for Abbott Laboratories (ABT)

A number of firms have modified their ratings and price targets on shares of Abbott Laboratories (NYSE: ABT) recently:

• 7/17/2026 – Abbott Laboratories had its price target raised by Citigroup Inc. from $108.00 to $112.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Abbott Laboratories had its “overweight” rating reaffirmed by Piper Sandler. They now have a $118.00 price target on the stock, up from $115.00.
• 7/17/2026 – Abbott Laboratories had its price target raised by JPMorgan Chase & Co. from $110.00 to $120.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Abbott Laboratories had its price target raised by Wells Fargo & Company from $109.00 to $112.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Abbott Laboratories had its “buy” rating reaffirmed by TD Cowen. They now have a $115.00 price target on the stock.
• 7/17/2026 – Abbott Laboratories had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $130.00 price target on the stock.
• 7/17/2026 – Abbott Laboratories had its price target raised by BTIG Research from $131.00 to $134.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Abbott Laboratories was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 7/1/2026 – Abbott Laboratories is now covered by Robert W. Baird. They set an “outperform” rating and a $121.00 price target on the stock.
• 6/30/2026 – Abbott Laboratories was upgraded by Robert W. Baird to “strong-buy”.
• 6/22/2026 – Abbott Laboratories had its “overweight” rating reaffirmed by Piper Sandler. They now have a $115.00 price target on the stock.
• 6/16/2026 – Abbott Laboratories was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/12/2026 – Abbott Laboratories had its price target lowered by Bank of America Corporation from $120.00 to $102.00.
• 5/27/2026 – Abbott Laboratories had its price target lowered by The Goldman Sachs Group, Inc. from $121.00 to $113.00. They now have a “buy” rating on the stock.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a $0.63 dividend. The ex-dividend date is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the firm’s stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the acquisition, the chief financial officer owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.